Data Sheet 1_Cost-effectiveness analysis based on two models of sacituzumab tirumotecan ve

A 580.1 KB document analyzes the cost-effectiveness of sacituzumab tirumotecan versus platinum-based chemotherapy for second-line treatment of EGFR-mutant non-small cell lung cancer in China. Lijun Jin authored this study, which uses data from the OptiTROP-Lung04 trial and was last updated on May 7, 2026. The analysis employs both a partitioned survival model and a Markov model to calculate incremental cost-effectiveness ratios.

Use Cases

• Evaluate health economic models based on partitioned survival and Markov model methodologies described in the study.
• Assess drug pricing and reimbursement strategies based on incremental cost-effectiveness ratio (ICER) calculations.
• Inform clinical decision-making for advanced EGFR-mutant NSCLC based on cost-effectiveness findings.
• Conduct sensitivity analyses on health economic outcomes based on parameters like progression free survival utility and drug price.

Strengths

• The analysis is based on clinical efficacy and safety data from the OptiTROP-Lung04 trial.
• Model robustness was tested via one-way and probabilistic sensitivity analyses, plus scenario analysis.
• The document provides specific incremental cost and QALY gain figures for two different economic models.

Limitations

• The dataset is a 580.1 KB DOCX file, suggesting limited scope and a focus on textual analysis rather than raw data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

Lijun Jin

Collection Method

Clinical efficacy and safety data were derived from the OptiTROP-Lung04 trial.

Freshness

Last updated 2026-05-07 05:42:40; freshness should be verified.

Geography

China's healthcare system